1-3 of 3
Ana Tari Ashizawa
Close
Sort by
Journal Articles

Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)

Maro Ohanian, Tara L. Lin, Ellen Ritchie, Michael Craig, Apurv Agrawal, Kathleen G. Halka, Naveen Pemmaraju, Gautam Borthakur, Miranda Lim, Sherry A. Pierce, Ana Tari Ashizawa, Hagop Kantarjian, Jorge E. Cortes, Gail J. Roboz
Journal: Blood
Blood (2021) 138 (Supplement 1): 1281.
https://doi.org/10.1182/blood-2021-152750
Published: 2021
Journal Articles

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

Maro N. Ohanian, DO, Tara L Lin, MD, Ellen K. Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Vinit Karur, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Sarah Aminov, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Natalie Sacarakis, Stacy Minor, Ana Tari Ashizawa, PhD, William Hahne, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1387.
https://doi.org/10.1182/blood-2018-99-113693
Published: 2018
Journal Articles

BP1001, a Novel Therapeutic for Chronic Myelogenous Leukemia

Ana Tari Ashizawa, PhD, Maro Ohanian, DO, Jorge E. Cortes, MD
Journal: Blood
Blood (2016) 128 (22): 4239.
https://doi.org/10.1182/blood.V128.22.4239.4239
Published: 2016